Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 183 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... February 25, 2021 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... July 16, 2020 EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... November 8, 2021 Load more HOT NEWS ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors 97-Year-Old Cancer Survivor Credits Her Success With Wanting To Attend A... Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her...
